Jing Li

US Patent:

20030032027, Feb 13, 2003

Filed:

Feb 12, 2002

Appl. No.:

10/073123

Inventors:

Jing Li - Flushing NY, US
Scott Powers - Greenlawn NY, US

International Classification:

C12Q001/68
G06F019/00
A61K048/00

US Classification:

435/006000, 702/020000, 514/044000

Abstract:

There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the WIP1 gene, which are amplified breast, and/or lung, and/or colon, and/or ovarian, and/or prostate cancer genes. The WIP1 gene, its expressed protein products and antibodies are used diagnostically or as targets for cancer therapy; they are also used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.

US Patent:

20030044814, Mar 6, 2003

Filed:

Feb 8, 2002

Appl. No.:

10/071838

Inventors:

Jing Li - Flushing NY, US
Scott Powers - Greenlawn NY, US
Phil Xiang - San Francisco CA, US
Yue Peng - South Setauket NY, US

Assignee:

Tularik Inc. - South San Francisco CA

International Classification:

C12Q001/68
G01N033/574
C12P019/34

US Classification:

435/006000, 435/007230, 435/091200

Abstract:

The present invention provides nucleic acid and protein sequences for a novel protein, PRC17, and methods, reagents, and kits for diagnosing and treating cancer in a mammal, e.g., a human. This invention is based upon the discovery that the novel PRC17 is overexpressed and/or amplified in cancer. Methods to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and to treat cancer, by inhibiting the expression and/or activity of PRC17 in a cancer cell are included.

US Patent:

20030099985, May 29, 2003

Filed:

Aug 27, 2002

Appl. No.:

10/228263

Inventors:

Jing Li - Flushing NY, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50
A61K048/00

US Classification:

435/006000, 702/020000, 514/044000

Abstract:

There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the C8FW gene, which are amplified breast and/or brain and/or colon and/or lung and/or prostate and/or ovarian cancer genes. The C8FW gene, its expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or vaccine; they are also used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.

US Patent:

20040005596, Jan 8, 2004

Filed:

Mar 18, 2003

Appl. No.:

10/390191

Inventors:

Jing Li - Flushing NY, US
Scott Powers - Greenlawn NY, US
Jianxin Yang - Commack NY, US

International Classification:

C12Q001/68
G01N033/574
C07H021/04
A61K048/00

US Classification:

435/006000, 514/044000, 536/023200, 435/007230

Abstract:

There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the CTSZ and CD24 genes, which are amplified colon cancer and/or ovarian cancer and/or breast cancer genes. The CTSZ and CD24 genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or vaccine; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.

US Patent:

20040005615, Jan 8, 2004

Filed:

May 22, 2003

Appl. No.:

10/443108

Inventors:

Jing Li - Flushing NY, US
David Mu - Jericho NY, US
Jianxin Yang - Commack NY, US

International Classification:

C12Q001/68
C07H021/04
C12P021/02
C12N005/06
A61K048/00
C07K014/705

US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 514/044000, 536/023500

Abstract:

There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the RecQL5, CTXL, USP13, MCL1, and Pellino1 genes, which are amplified in many types of cancer. The RecQL5, CTXL, USP13, MCL1, and Pellino1 genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or as vaccines; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.

US Patent:

20040171037, Sep 2, 2004

Filed:

Nov 18, 2003

Appl. No.:

10/715117

Inventors:

Jing Li - Flushing NY, US
Scott Powers - Greenlawn NY, US
Wun Sin - Dix Hills NY, US
Jianxin Yang - Commack NY, US

International Classification:

C12Q001/68
A61K048/00

US Classification:

435/006000, 514/044000

Abstract:

There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing genes, which are amplified in many types of cancer. The amplified genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or as vaccines; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.

US Patent:

20120152175, Jun 21, 2012

Filed:

Dec 20, 2010

Appl. No.:

12/928801

Inventors:

Jing Li - Flushing NY, US

International Classification:

A01K 29/00

US Classification:

119161

Abstract:

Training pad for housebreaking young dogs consisting of absorbent material imprinted with a circle which is impregnated with scented blue ink, contains SAP in the center, and backed by water impervious polyethylene which attracts young dogs to urinate only in the circle part of the pad.

US Patent:

20130223121, Aug 29, 2013

Filed:

Feb 29, 2012

Appl. No.:

13/407813

Inventors:

Leland Chang - New York NY, US
Chung H. Lam - Peekskill NY, US
Jing Li - Ossining NY, US
Robert K. Montoye - Rochester MN, US

Assignee:

International Business Machines Corporation - Armonk NY

International Classification:

G11C 15/00

US Classification:

365 4915

Abstract:

A sensing circuit and method for sensing match lines in content addressable memory. The sensing circuit includes an inverter electrically coupled in a feedback loop to a match line. The inverter includes an inverting threshold of the match line. The match line is charged to substantially a first voltage threshold during a pre-charge phase. An evaluation phase occurs when the match line voltage drops from substantially the first voltage threshold to substantially the second voltage threshold.